Mounting evidence supports a major role for the Na + /H + exchanger NHE1 in cancer progression and metastasis.
Introduction
The Na + /H + exchanger isoform 1 (NHE1 [SLC9A1]) is the major protein involved in the regulation of pH homeostasis and is ubiquitously expressed in mammalian cells. Human NHE1 is an integral plasma membrane protein comprised of 815 amino acids. The N-terminal transmembrane domain consisting of amino acids 1 to 500 is responsible for ion exchange, and the C-terminal cytosolic domain of amino acids 501 to 815 regulates the exchanger's activity via phosphorylation or interactions with intracellular signalling molecules [1, 2] . In normal cells, NHE1 is activated either by growth factors and hormones in serum, which leads to direct or indirect phosphorylation of the exchanger by intracellular signal kinases (e.g. PI3K, ERK1/2, p38MAPK), or by binding to a variety of cytosolic proteins and lipids (e.g. ezrin-radixin-moesin, 14-3-3, calmodulin, phosphatidylinositol 4,5-biphosphate (PIP 2 ), carbonic anhydrase; reviewed in [3, 4] ). This activation is due to an increased affinity of NHE1's allosteric proton-binding site for intracellular H + ions [4] . In cancer cells, however, exchanger activity is dysregulated and NHE1 becomes overactive. The increased activity of NHE1 is pivotal to tumourigenesis. It results in increased sodium uptake and elevated proton extrusion that leads to intracellular alkalinization of cancer cells and extracellular acidification of the tumour microenvironment [5, 6] . In breast cancer, the dysregulation of pH homeostasis and altered dynamics of proton transport are critical determinants of metastasis.
Elevated intracellular pH with decreased extracellular pH is thought to lead to enhanced cellular proliferation and metastasis [6] . Breast cancer is a heterogeneous disease with three major molecular profiles: estrogen and/or progesterone receptor (ER/PR)-positive; human epidermal growth factor receptor 2 (HER2)-positive; and triple-negative, which lacks the expression of estrogen, progesterone, or HER2 receptors [7] . In breast cancer cells, NHE1 becomes hyperactive early in neoplastic transformation. This hyper-activation has been shown to be particularly important in triple negative breast cancer [8] where it is primarily responsible for the acidic pH of the tumour microenvironment that facilitates metastasis [5] . Inhibiting NHE1 activity, or preventing the dysregulation of NHE1, may thus provide an attractive avenue for preventing metastasis of breast cancer [3, 8] . This is particularly important for aggressive metastatic triple-negative breast cancer for which hormone and HER2-targeted therapies do not work [9] .
NHE1 regulation is mediated through its cytosolic C-terminal tail by both phosphorylation and protein-protein interactions. Phosphorylation of NHE1 directly increases exchanger activity in response to hormonal stimulation; however, protein-protein interactions are thought to account for approximately 50% of NHE1 activation by growth factors. These protein interactions are increasingly considered to be important in NHE1 regulation [3, [10] [11] [12] [13] . NHE1 hyper-activation could be due to an altered regulation of the exchanger's activity by signal kinases and its intracellular binding partners. We recently demonstrated that NHE1 regulation by p90
RSK via the serine 703 residue can influence the metastatic potential of triple-negative breast cancer cells. Additionally, the metastatic potential of breast cancer cells was enhanced by mutation of the calmodulin-binding domain to make an artificially hyperactive NHE1 protein [14] . There has been increasing attention on the role of NHE1 as a signal scaffold in recent years. NHE1 binds signalling complexes including ERK2 in Chinese hamster ovary cells [15, 16] . It acts as an anchor for actin filaments [13] and binds several regulatory proteins including calmodulin [1] , HSP70 [17] and others (reviewed in [4] ). As noted above, the enhanced activity of NHE1 is critical in metastasis and the proteinmediated regulation of NHE1 is likewise crucial in its activity. However, there is no information available on protein-mediated regulation of NHE1 in breast cancer cells, particularly in the triple-negative breast cancer (TNBC) subtype.
In the present study, affinity chromatography followed by mass spectrometry was used to identify intracellular protein binding partners of NHE1 in a triple-negative breast cancer model, MDA-MB-231 cells. We further validated key intracellular molecular associations that make up the NHE1 interactome in these cells by co-immunoprecipitation. Our data was supplemented by an analysis of The Cancer Genome Atlas (TCGA; https://tcga-data.nci.nih.gov/tcga/) database, where we compared NHE1 gene expression in primary patient breast tumours and normal breast tissue. Reverse phase protein array (RPPA) clinical data from TCGA was used to examine correlations in NHE1 mRNA expression with that of signal proteins of primary breast tumours by subtype versus normal tissue. We also looked for correlations between NHE1 expression and other interacting proteins or signal kinases. Our data, for the first time, provide insight into the NHE1 signal scaffold that regulates metastasis in triple-negative basal-like breast cancer and could provide critical insights for the development of novel chemotherapeutics targeted towards TNBC.
Materials and methods

Cell lines and culture conditions
MDA-MB-231 breast cancer cells were cultured in high-glucose modified DMEM (HyClone) supplemented with 10% fetal calf serum (HyClone), 10 mM HEPES, and 1000 units/ml penicillin/streptomycin (Gibco) under standard culture conditions (5% CO 2 , 37°C and high humidity). Low serum media, to activate NHE1, contained 0.2% serum but was otherwise identical in composition. We used a previously generated stable MDA-MB-231 cell line where the endogenous NHE1 was knocked out [8] and replaced with a hemagglutinin (HA) tagged NHE1 protein that does not interfere with NHE1 activity [18] . Cells expressing wild-type HA-tagged NHE1 protein were grown in the presence of 400 μg/ml G418 (Geneticin Sulfate, Santa Cruz). DNA analysis (DDC Medical, Ohio) was used to authenticate parental MDA-MB-231 cells, which showed N 95% homology to the ATCC STR profile.
Preparation of cell lysates
Seventy-five 150 mm plates of MDA-MB-231 cells were grown in standard medium and lysis buffer [20 mM HEPES, 1 mM EDTA, 1 mM EGTA, 1 mM PMSF, 1% Triton X-100, and protease inhibitors] was added to generate whole cell lysates. Lysates were centrifuged at 10,000 rpm for 15 min. at 4°C and the supernatant was used for affinity chromatography.
Protein expression and purification
Affinity chromatography was used to identify the interacting protein partners of NHE1 in MDA-MB-231 breast cancer cell lysates as previously described [19] . The C terminus of the rabbit NHE1 spanning amino acids 545 to 816 was produced as a glutathione S-transferase (GST) fusion protein [17] . The primer pair used for amplification of the sequence was 5′-acggatccattggaaagacaagctcaaccggttta-3′ and 5′-aagaattcactgccctttggggatgaaaggct-3′. For cloning and expression, the pGEX-3X plasmid in the BamHI-EcoRI sites was utilized. GST was produced using the same plasmid without an exogenous insert (control). Proteins were expressed in TOP2 Escherichia coli and a single colony was selected for overnight culture. After induction for 5 h at 30°C with isopropyl β-D-thiogalactopyranoside, bacterial cultures were centrifuged in lysis buffer at 7000 rpm at 4°C prior to sonication of the pellet to induce greater cell disruption and protein extraction. Debris was removed by further centrifugation at 20,000 rpm at 4°C and the supernatant collected and filtered before transferring to column. Purification from the supernatant was essentially as described earlier [19] using a glutathionine-agarose column. The supernatant was loaded onto the column and passed through it twice. The column was washed with 20 volumes of phosphate buffered saline and eluates with the purified protein were collected and centrifuged at 3000 ×g. Purified proteins were resuspended in 0.1 M MOPS buffer with 80 mM CaCl 2 (pH 7.5) and concentrated. Five milligram of either GST or NHE1-GST proteins were bound to Affi-Gel 10 beads (Bio-Rad) as described by the manufacturer. After blockage of any remaining reactive esters and washing, MDA-MB-231 cell lysates were then passed through the Affi-Gel 10 column 10 times and the column was washed. Bound proteins were eluted with buffer [20 mM HEPES, pH 7.2, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF, 1% SDS and protease inhibitors], and precipitated with trichloroacetic acid. Precipitates were separated by SDS-PAGE and separated proteins were cut from the gel for further analysis by mass spectrometry.
Sample preparation and mass spectrometry
The samples were digested with trypsin in-gel. Briefly, the excised gel bands were de-stained twice in 100 mM ammonium bicarbonate/ acetonitrile (50:50) . The samples were then reduced with 10 mM BME in 100 mM bicarbonate and the alkylated with 55 mM iodoacetamide in 100 mm bicarbonate. After dehydration, gel segments were digested with trypsin (6 ng/μL) overnight at room temperature. Tryptic peptides were extracted from the gel with a 97% water/2% acetonitrile/1% formic acid solution, followed by a second extraction using 50% of the first extraction buffer and 50% acetonitrile.
Fractions containing tryptic peptides dissolved in aqueous 25% v/v acetonitrile and 1% v/v formic acid were resolved and ionized by using nanoflow HPLC (Easy-nLC II, Thermo Scientific) coupled to the LTQ XL-Orbitrap hybrid mass spectrometer (Thermo Scientific). Nanoflow chromatography and electrospray ionization were accomplished by using a PicoFrit fused silica capillary column (ProteoPepII, C18) with 100 μm inner diameter (300 Å, 5 μm, New Objective). Peptide mixtures were next injected onto the column with a flow rate of 3000 nL/min and were resolved at 500 nL/min using 70 min linear gradients from 0 to 45% v/v aqueous ACN in 0.2% v/v formic acid. The mass spectrometer was operated in a data-dependent acquisition mode, recording high-accuracy and high-resolution survey Orbitrap spectra using external mass calibration, with a resolution of 60,000 and m/z range of 400 to 2000. The fourteen most intense multiply charged ions were sequentially fragmented using collision-induced dissociation, and the spectra of their fragments were recorded in the linear ion trap. After two fragmentations, all precursors selected for dissociation were dynamically excluded for 60 s.
Data were processed using Proteome Discoverer 1.4 (Thermo Scientific) and SEQUEST was used to search the Uniprot Human protein database (Thermo Scientific). Search parameters included a fragment mass tolerance of 0.8 Da and a precursor mass tolerance of 10 ppm. Peptides were searched with the dynamic modifications of carbamidomethyl cysteine as a static modification and oxidized methionine and deamidated glutamine and asparagine. Data shown are representative of three independent experiments.
Co-immunoprecipitation and immunoblotting
Cells were stimulated (+, 0.2% serum) or not (−, 10% serum) overnight prior to adding 2.5 mM DSP (dithiobis[succinimidyl propionate]), an amine-reactive cleavable cross-linker (Thermo Scientific). Incubation with DSP was for 2 h on ice in the dark. The reaction was stopped with 30 mM Tris (Fisher BioReagents) for 15 min. Prior to lysis with RIPA buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 80 mM NaF, 5 mM EDTA, 1 mM EGTA, 1 mM Na-orthovanadate, 1% NP-40, 0.05% deoxycholate and protease inhibitor cocktail). After centrifugation, 25 μL of pre-washed HA-tagged beads (Santa Cruz Biotechnology) was added to the supernatant and incubated overnight at 4°C. Beads were removed by centrifugation and washed with phosphate buffered saline (PBS, 150 mM NaCl, 5 mM sodium phosphate, pH 7.4). Samples were boiled in SDS before separation on SDS-PAGE gels. Western blotting was onto nitrocellulose membranes. Co-immunoprecipitation of putative protein interaction partners of NHE1 was confirmed by immunoblot analysis. Blots were incubated overnight with the following antibodies against targeted proteins: AKT (Cell Signalling Technologies); α-Enolase (ProteinTech); HA-probe, CHP1 and 14-3-3 (Santa Cruz Biotechnologies); and HSP70 and HSP90 (Enzo Life Sciences). Chemiluminescence was used to detect immunoreactive co-precipitating proteins.
Bioinformatics
An analysis of primary patient clinical samples in The Cancer Genome Atlas (TCGA; https://tcga-data.nci.nih.gov/tcga/) database was used to evaluate NHE1 gene expression in normal breast tissue versus primary breast tumours. Level 3 TCGA RNAseqV2 gene expression, reverse phase protein array (RPPA), and clinical data from 1062 breast cancer and 113 associated normal patient samples were obtained from the TCGA Data Portal (https://tcga-data.nci.nih.gov/tcga/) in August 2014. Subtype data for tumours was accessed from the UCSC cancer genome browser (RNASeqV2 defined). All statistical analyses and visualizations for bioinformatics datasets were conducted in the RStudio programming environment (v0.98.501). R/Bioconductor packages ggplot2 and plyr were used where appropriate.
Results
Determination of NHE1 interacting partners by mass spectrometry
We used mass spectrometry analysis in order to determine potential novel intracellular interaction partners of NHE1 in triple-negative MDA-MB-231 breast cancer cells (Table 1 ). An affinity chromatography-based protein purification method using a glutathione S-transferase (GST) fusion protein of the C terminus of the rabbit NHE1 spanning amino acids 545 to 816 (NHE1-GST) was used to detect protein-protein interactions in MDA-MB-231 cell lysates. Interacting proteins unique to the NHE1-GST sample were selected based on the number of detected peptide spectral matches (PSM). The highest number of PSMs was attributed to NHE1 (SLC9A1), indicating the presence of NHE1 homodimers, which has been reported earlier [20] . Several proteins involved in cellular biosynthesis, metabolism, signal transduction, and cytoskeletal organization were found to uniquely interact with NHE1 (over the control) as listed in Table 1 . For interacting proteins present in both the GST control and the NHE1-GST sample, the binary logarithm of the ratio of the number of PSMs in the sample versus control was calculated (log2[PSM NHE1-GST /PSM GST ]). A two-fold or higher detection of interacting proteins in the sample over the control was considered significant (Table 2) .
Validation of NHE1 interaction partners by co-immunoprecipitation
We validated several putative intracellular protein binding partners of NHE1, both as determined by the above MS analysis and previous studies (reviewed in [3] ), by co-immunoprecipitation of HA-tagged NHE1 with target proteins. In breast cancer cells, NHE1 becomes hyper-active (stimulated) with serum deprivation [14, 21, 22] . We cultured MDA-MB-231 cells in stimulated (+, serum-deprived, 0.2% serum) and unstimulated (−, serum-supplemented, 10% serum) conditions prior to lysis and co-immunoprecipitation. This was followed by immunoblotting with antibodies against target proteins. NHE1 was found to co-immunoprecipitate with: AKT (protein kinase B, PKB), α-enolase, CHP1 (calcineurin homologous protein 1), 14-3-3, and heat shock proteins HSP70 and HSP90 [ Fig. 1; N = 3] . No significant differences in the interaction of NHE1 with AKT, CHP1, HSP70 or HSP90 were observed between stimulated and unstimulated cells. However, in stimulated MDA-MB-231 cells where basal NHE1 exchange activity is significantly higher [14, 21] , the dimeric form of 14-3-3 was associated with NHE1 in greater amounts than the monomeric form. Also, α-enolase is mainly associated with NHE1 in stimulated cells. The Cancer Genome Atlas (TCGA; www.cancergenome.nih.gov), an initiative of the National Cancer Institute and the National Human Genome Research Institute, is a cancer genomic database containing tumour tissue and normal tissue samples from hundreds of patients. We used TCGA to analyze the expression of NHE1 mRNA in primary breast tumours and associated normal mammary tissue from patient samples (n = 1062 and 113, respectively). Our analysis revealed that NHE1 mRNA expression significantly increased in breast tumour samples over their matched normal counterparts (Fig. 2a , *P b 0.001). When expression levels were examined by breast cancer subtype, however, we found significantly decreased NHE1 expression in the basal subtype compared to luminal and HER2 + subtypes [23] (Fig. 2b , *P b 0.001). Though NHE1 expression levels tended to be higher than normal in HER+ tumours, this effect was not significant.
Reverse phase protein array (RPPA) analysis of NHE1 interacting partners from primary patient tumours
Reverse phase protein arrays (RPPA) are a high-throughput, antibody-based determination of protein expression levels in primary patient tumour tissue samples from TCGA. We analyzed correlations of NHE1 mRNA expression with that of proteins in primary tumours from patients with the basal (triple-negative) clinical subtype of breast cancer using the RPPA-TCGA database (N = 220). As seen in Table 3 Table 3 ).
Discussion
NHE1 is regulated by both kinase-mediated phosphorylation and by interactions with intracellular proteins and lipids that modulate its activity. These regulators primarily affect NHE1 activity by shifting its pH versus activity curve to make it more active at more alkaline intracellular pH [3, [11] [12] [13] . In transformed cells, cytoplasmic alkalinization brought about by increased Na + uptake is largely driven by NHE1 and is a critical step in tumourigenesis. The resultant increased H + efflux also mediates metastasis by providing a more acidic extracellular microenvironment that not only promotes the development of a more invasive cell phenotype [6] , but is also optimal for the activity of secreted serine proteases and matrix metalloproteinases. These proteolytic enzymes digest a path through the extracellular matrix allowing for cells to leave the primary tumour and enter the bloodstream [24, 25] . It is also of note that elevated NHE1 activity contributes to sodium loading of cells. Elevated sodium loading by NHE1 and other sodium loading proteins such as sodium channels and Na + /HCO 3 -co-transport, may promote mitogenesis and/or oncognesis [26] [27] [28] [29] [30] and elevated tissue sodium is reported in malignant breast cancer [31] and other cancer types [32, 33] . Thus elevated NHE1 activity may contribute to oncogenesis by more than one mechanism. Since the elevated activity of NHE1 contributes to metastasis, there is great interest in deciphering how this activity is regulated in breast cancer cells. In other tissues, the cytosolic C-terminal tail of NHE1 is a binding site for signal kinases, regulatory proteins, and linkages to the cell cytoskeleton [4, 13, 15, 16] suggesting that it is acting as a scaffolding rather than an adaptor protein. In this study, we used different approaches to identify individual molecular players associated with the NHE1 signal scaffold in breast cancer. We looked at direct interactions determined by affinity chromatography and identified by mass spectrometry and we also analyzed hundreds of primary patient tumour samples characterized by The Cancer Genome Atlas.
NHE1 and cytoskeletal proteins
Our affinity chromatography experiments identified alpha-actinin-4, moesin, ezrin, F-actin-capping protein, talin-1, profilin and alphaactinin-1 (Tables 1, 2) as cytoskeletal proteins from MDA-MB-231 cells that were associated with the cytosolic tail of NHE1. Our study is the first identification of the association of most of these proteins with NHE1 in this cell type, which is representative of basal triple-negative breast cancer. However, many of these and related proteins have been suggested to be involved with NHE1 in other cell types. Ezrin and moesin (and radxin) are known to bind to NHE1 [34] ; in fact, ezrin colocalizes with NHE1 in MDA-MB-231 cells [35] . We also found talin-1 associated with NHE1. Talin the actin cytoskeleton, binds moesin, and recruits a moesin-NHE1 complex to invadopodia, stabilizing them and promoting matrix degradation [36] .
Our results also revealed novel interactions of NHE1 with the actinbinding proteins alpha-actinin 1 and 4, and profilin-1 in MDA-MB-231 cells. Alpha-actinin-1 and 4 are the non-muscle isoforms of the protein generally believed to be structural components of F-actin cohesion in cells [37] . Alpha-actinin-4 is upregulated in some types of cancer and promotes proliferation of luminal MCF-7 breast cancer cells [37, 38] . Profilin is a ubiquitously expressed actin-binding protein that can regulate invadopodia maturation [39] and is overexpressed in breast cancer cells [40] . To our knowledge, profilin-1 has not been previously shown to be associated with NHE1, and this interaction is intriguing considering its role in invadopodia maturation [39] . However, we were unable to confirm these interactions further by co-immunoprecipitation.
NHE1 and chaperone proteins
Various chaperone proteins were also identified as associating with NHE1 by affinity chromatography, including heat shock proteins. We confirmed the interaction of HSP70 and HSP90 with NHE1 by co-immunoprecipitation. NHE1 and HSP70 were previously shown to interact in PS127A Chinese hamster fibroblasts [17] . More recently [41] , HSP70 was found to be dynamically associated with NHE1 in macrophages. Heat shock proteins are inducible molecular chaperones that facilitate the folding of proteins and their transport across membranes, and prevent protein aggregation in response to cellular stress. Tumour cells express higher levels of HSP70 and HSP90, which play a role in metastasis, proliferation and protection against apoptosis [42] . This leaves open the possibility that some of their actions are mediated through NHE1, which also facilitates tumour cell metastasis [8, 14] . Ubiquitously expressed kinase inhibitor protein involved in cell cycle regulation [70] . −0.24 0.032 Chk1
Serine/threonine kinase involved in G2/M cell cycle arrest and DNA damage repair [71] . −0.25 0.028 Smad4 Involved in TGF β signalling which plays a role in breast cancer carcinogenesis [72] . −0.25 0.025 Cyclin B1
Regulatory subunit of cyclin-dependent kinase 1 (CDK1); important for entry into mitosis [73] . Other chaperones found associated with NHE1 included protein disulfide isomerase, peroxiredoxin-2, thioredoxin, calnexin and calreticulin. These proteins are likely involved in the folding of NHE1. Several laboratories [43, 44] have shown that elevated NHE1 expression is associated with increased calreticulin and protein disulfide isomerase expression, implicating an association of some of these proteins with NHE1 in other tissues. Glucose-regulated proteins were also increased with elevated NHE1 expression in the myocardium [43] . Here, we found an association of 78 kDa glucose-regulated protein with NHE1 (Table 2) . Endoplasmin, which was also found associated with the NHE1 tail (Table 1) , is known to be elevated in breast cancer with distant metastasis and is associated with decreased patient survival [45] .
NHE1 and biosynthetic proteins
We identified several proteins of biosynthetic pathways associated with NHE1 including glutamate dehydrogenase, fructose-bisphosphate aldolase, transketolase, glyceraldehyde-3-phosphate dehydrogenase and α-enolase (Tables 1, 2 ). α-enolase is a cytosolic glycolytic enzyme and oxidative stress protein. Its expression is elevated in many tumours, including those of the breast, where it is also found on the cell surface [46, 47] . The NHE1-α-enolase complex was confirmed by both affinity chromatography and co-immunoprecipitation. Interestingly, α-enolase was found to be more strongly associated with NHE1 from cells cultured in stimulated, serum-depleted conditions where the exchanger is hyperactive. The physiological significance of such associations are not clear; however, glycolytic enzymes are known to bind to other membrane proteins, such as band 3, and the binding process assists in regulation of metabolism [48] . Whether NHE1 plays a similar role is not known. The only kinase found to be directly associated with the NHE1 cytosolic tail in affinity chromatography experiments was phosphoglycerate kinase, which plays a role in regulating the glycolytic pathway.
NHE1 and signal transduction proteins
Calcineurin homologous protein 1 (CHP1) has been shown to form a complex with the cytosolic domain of NHE1, helping to stabilize it at the cell surface in some cell types [4, 49] . Surprisingly, we did not find CHP1 associated with NHE1 by affinity chromatography experiments but were able to demonstrate an association with NHE1 through co-immunoprecipitation from MDA-MB-231 cells. Other proteins found associated with NHE1 by affinity chromatography experiments included: cathepsin D, galectin 1, voltage-dependent anion selective channel protein 1, a chloride channel, a 40s ribosomal protein SA, nucleolin and heterogeneous nuclear ribonucleoprotein A1. Some of these proteins have an association with cancer progression. For example, cathepsin D is a lysosomal protease overexpressed in many metastatic breast cancer cell lines and its presence in the cytosol of primary breast tumours is indicative of an increased risk of metastatic disease [50] . Galectin-1 is a β-galactosidase-binding protein thought to be involved in cell-cell interactions. It is abnormally expressed in cancer cells and increased expression in many cancers, including breast cancer, is generally associated with poor prognosis [51] . Nucleolin is also overexpressed in breast cancer cell populations [52] . Our attempts to validate the interaction of cathepsin D with NHE1 by co-IP experiments were unsuccessful; validation of the other protein-protein interactions were not attempted at this time.
Significantly, we identified several isoforms of 14-3-3 proteins that bind to the NHE1 tail region by affinity chromatography (Tables 1, 2) and this was confirmed by co-immunoprecipitation experiments. 14-3-3 proteins bind intracellular ligands which include signal kinases, phosphatases and other proteins. The 14-3-3 proteins have been demonstrated to interact with the NHE1 tail. They regulate phosphorylation of serine 703 of NHE1 in the muscle tissues [53, 54] . 14-3-3 binding to NHE1 in breast cancer cells has not been reported. We have, however, previously demonstrated that serine 703, the binding site of 14-3-3 on the NHE1 C-terminal, plays an important role in the regulation of epithelial-mesenchymal transition of triple-negative MDA-MB-231 breast cancer cells [14] . These results support the suggestion that 14-3-3 binding to NHE1 is important in the regulation of the exchanger in TNBC cells. Furthermore, this data also supports the idea that NHE1 is acting more as a scaffold protein, as opposed to just an adaptor protein, with definitive functional consequences to many of these interactions as suggested earlier [15] .
NHE1 expression and protein associations in primary patient breast tumours
To supplement the above findings, we examined correlations in the expression of NHE1 and other signal proteins in primary patient tumours. We previously used the ONCOMINE™ database [21] to show that, in a comparison of multiple cancers versus matched normal tissue, NHE1 mRNA expression is elevated in some types of cancer including breast cancer. In this study, we used The Cancer Genome Atlas (TCGA) to analyze NHE1 mRNA expression in primary patient breast tumours of various clinical subtypes. The TCGA is a more robust RNA-sequencing database with a much larger patient breast tumour and normal tissue cohort. The TCGA also has an additional analytic capability linked to a reverse phase protein array (RPPA) database that enables the comparison of the expression of multiple proteins with a particular gene of interest. A limitation is that NHE1 expression can only be determined at the mRNA level in currently available tumour genomics databases. Despite this limitation, useful information can still be collected from this analysis that will lead to further investigations.
Our initial TCGA analysis showed that NHE1 mRNA expression was significantly higher in breast tumours than in normal mammary tissue (Fig. 2a) . Interestingly, a more in-depth analysis classified by specific breast cancer subtypes (luminal A and B, HER2-amplified and basal) revealed that NHE1 mRNA expression is mostly unchanged in luminal and HER2-amplified tumours and actually lower in basal (triple-negative) tumours compared to normal mammary tissue (Fig. 2b) . The reason for this discrepancy is unclear. However, it is possible that, based on the sample sizes for the two analyses (see legends for Fig. 2a and b) , the subtype-specific tumour tissues in Fig. 2b may only account for a percentage of the sample pool used to generate Fig. 2a .
The lower NHE1 mRNA expression in basal breast tumours may be indicative of a likewise lower expression of NHE1 protein. At first glance, this result appears to contradict the suggestion that NHE1 plays an important role in breast tumour progression. Particularly since the basal subtype represents the most aggressively metastatic cancers. However, NHE1 is a tightly regulated protein that is modulated by both phosphorylation and protein binding, and the regulation of its activity is critical in metastatic basal-like breast cancer cells. More NHE1 protein, if inactive, would not affect intracellular pH. Several laboratories, including ours, have shown that NHE1 is hyper-activated in breast cancer cells in the acidic, hypoxic, and serum-depleted tumour microenvironment [5, 8, 14] ; in our studies, this increased activity was not accompanied by a similar increase in NHE1 protein expression. In heart disease an analogous situation exists. The activation of NHE1, and not increased expression of the protein per se, is the critical factor determining NHE1-mediated disease progression [55] . Further to this end, we recently demonstrated that replacement of endogenous NHE1 in MDA-MB-231 cells with a hyperactive NHE1 protein resulted in an increased metastatic behaviour of this cell line [14] . This also supports the hypothesis that activation and regulation of NHE1 are critical determinants.
We used the TCGA-RPPA database to identify correlations between NHE1 mRNA expression and a number of intracellular signalling molecules. We found several novel, as well as previously identified, potential regulators of the protein. p90 RSK and AKT (protein kinase B) are known to regulate NHE1 activity. p90 RSK phosphorylates NHE1 at Ser703 and stimulates its activity, mediating growth factor activation of the protein in some cell types [4, 56] . We recently showed that a mutation at serine 703 to non-phosphorylatable alanine markedly changed the morphology of MDA-MB-231 breast cancer cells from a mesenchymal to a more epithelial-like phenotype with a concomitant loss of metastatic potential [14] . In this study, we found a weak but significant positive correlation between NHE1 mRNA and the expression of phosphorylated p90 RSK at the protein level in primary metastatic basal (triple-negative), but not luminal, breast tumours (Fig. 3) . This leaves open the possibility that p90 RSK -mediated phosphorylation of NHE1 is at least partially responsible for the aggressive metastatic behaviour of TNBC cells. Indeed, we have previously demonstrated that BI-D1870, a specific inhibitor of p90 RSK , inhibits the metastatic potential of several TNBC cell types, supporting this hypothesis [14] . Though these results are significant, the pattern of the positive correlation is dispersed. The reason for this is not immediately clear but could be due to the influence of other NHE1 regulators.
Another kinase known to regulate NHE1 is AKT. The exact role of AKT-mediated phosphorylation of NHE1 is dependent on cell type [4] . In the myocardium, NHE1 activity is inhibited by AKT-mediated phosphorylation of serine 648 [57, 58] . However, in fibroblasts, AKT phosphorylation of NHE1 is stimulatory, induces cytoskeletal remodeling, and is necessary for the activation of NHE1 by insulin and PDGF [59] . We confirmed that AKT interacts with NHE1 in MDA-MB-231 cells by co-immunoprecipitation experiments (Fig. 1) . TCGA-RPPA analysis showed that AKT protein expression in patient tumours of the triplenegative basal clinical subtype positively, correlated with NHE1 expression though weakly (Table 3) .
Other proteins that were found to weakly, positively correlate with NHE1 in RPPA were pGSK3, NF2, Src and β-catenin. To our knowledge, the direct demonstration of these correlations with NHE1 in triplenegative breast cancer would be novel and could be the subject of future investigations. Potential phosphorylation sites for GSK3 exist [4] . The expression of some proteins negatively correlated with NHE1 mRNA expression ( Table 3 ). The significance of this is not yet clear.
Conclusion
In breast cancer, the dysregulation of pH homeostasis chiefly caused by hyper-activation of NHE1 plays a critical role in triggering and sustaining metastasis, where altered dynamics of Na + /H + exchange are a key determinant of metastatic potential. This hyper-activation of NHE1 is particularly important in triple-negative breast cancer where it is primarily responsible for the acidic pH of the tumour microenvironment that facilitates metastasis [5, 6, 8] . NHE1 is regulated by proteinprotein interactions and by phosphorylation/dephosphorylation. Here, we examined proteins binding to NHE1 in triple-negative breast cancer cells and those correlating with NHE1 gene expression in primary patient breast tumour samples. We found many categories of proteins binding to the NHE1 regulatory cytosolic domain including several cytoskeletal, chaperone, biosynthesis, and signalling proteins. It is noteworthy that many NHE1-binding proteins have elevated expression in breast and other cancer types; this raises the possibility that their function could impact NHE1 activity (or vice versa) and contribute to its role in metastasis. Our study is the first definition of the interactome of NHE1 in triple-negative breast cancer cells.
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